Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR002210)
Formula Reactant Rucaparib Product Rucaparib M323 metabolite
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 2D6 (CYP2D6) DME Info
Cytochrome P450 3A4 (CYP3A4) DME Info
Cytochrome P450 1A2 (CYP1A2) DME Info
Metabolic Type Oxidation - Oxidation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR002212 Rucaparib Rucaparib M309 metabolite Oxidation - N-Demethylation Rucaparib [1]
MR002211 Rucaparib Rucaparib M324 metabolite Oxidation - Oxidation Rucaparib [1], [2]
MR002213 Rucaparib Rucaparib M337b metabolite Oxidation - Oxidation Rucaparib [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR002207 Rucaparib M323 metabolite Rucaparib M337a metabolite Conjugation - N-Methylation Rucaparib [1]
MR002208 Rucaparib M323 metabolite Rucaparib metabolite M337C Conjugation - N-Methylation Rucaparib [1]
References
1 Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors Invest New Drugs. 2020 Jun;38(3):765-775. doi: 10.1007/s10637-019-00815-2.
2 Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemother Pharmacol. 2021 Aug;88(2):259-270. doi: 10.1007/s00280-021-04278-2.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.